LUC00035I2 - - Google Patents

Info

Publication number
LUC00035I2
LUC00035I2 LU00035C LUC00035C LUC00035I2 LU C00035 I2 LUC00035 I2 LU C00035I2 LU 00035 C LU00035 C LU 00035C LU C00035 C LUC00035 C LU C00035C LU C00035 I2 LUC00035 I2 LU C00035I2
Authority
LU
Luxembourg
Application number
LU00035C
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37801586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00035(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of LUC00035I1 publication Critical patent/LUC00035I1/fr
Publication of LUC00035I2 publication Critical patent/LUC00035I2/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU00035C 2005-11-01 2017-09-25 LUC00035I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73222105P 2005-11-01 2005-11-01
PCT/US2006/042258 WO2007053533A2 (fr) 2005-11-01 2006-10-27 Solution de chlorure de sodium pour la reconstitution ou la dilution de medicaments

Publications (2)

Publication Number Publication Date
LUC00035I1 LUC00035I1 (fr) 2017-09-28
LUC00035I2 true LUC00035I2 (fr) 2017-12-01

Family

ID=37801586

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00035C LUC00035I2 (fr) 2005-11-01 2017-09-25

Country Status (31)

Country Link
US (4) US20070135343A1 (fr)
EP (3) EP3225233B1 (fr)
JP (1) JP5555425B2 (fr)
KR (2) KR20110128957A (fr)
CN (1) CN101351190B (fr)
AR (2) AR056748A1 (fr)
AU (1) AU2006308921C1 (fr)
BR (1) BRPI0618133A2 (fr)
CA (1) CA2626531C (fr)
CR (1) CR9958A (fr)
DK (2) DK3225233T3 (fr)
EC (1) ECSP088485A (fr)
ES (2) ES2749574T3 (fr)
FI (1) FI1942868T4 (fr)
FR (1) FR20C1005I1 (fr)
GT (1) GT200800037A (fr)
HK (1) HK1245090B (fr)
HU (4) HUE045421T2 (fr)
IL (1) IL190843A (fr)
LU (1) LUC00035I2 (fr)
MY (1) MY184364A (fr)
NO (1) NO347263B1 (fr)
NZ (1) NZ567685A (fr)
PE (3) PE20070714A1 (fr)
PL (2) PL1942868T5 (fr)
PT (2) PT1942868T (fr)
RU (1) RU2432157C2 (fr)
SI (2) SI1942868T2 (fr)
TW (1) TWI480063B (fr)
UA (1) UA97234C2 (fr)
WO (1) WO2007053533A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA97234C2 (ru) 2005-11-01 2012-01-25 Уайєт Раствор хлорида натрия для восстановления влагосодержания композиции лиофилизированного фактора ix
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US8431011B2 (en) * 2008-01-31 2013-04-30 Abbott Diabetes Care Inc. Method for automatically and rapidly distinguishing between control and sample solutions in a biosensor strip
KR101614983B1 (ko) * 2009-11-17 2016-04-22 입센 파마 에스.에이.에스 Hgh 및 rhigf―1의 조합물을 위한 제제
US10634741B2 (en) 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
US9427186B2 (en) 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
EA031209B9 (ru) 2010-01-15 2021-11-19 Кирин-Эмджен, Инк. Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
SG10201913700SA (en) 2010-07-09 2020-03-30 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
HK1213521A1 (zh) * 2012-09-25 2016-07-08 Bioverativ Therapeutics Inc. Fix多肽的應用
CN105283202B (zh) 2013-03-11 2019-04-23 安都磁学有限公司 用于淋巴结检测的低渗溶液
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
EA037906B1 (ru) * 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
EP3123090A4 (fr) * 2014-03-24 2017-12-13 Bioverativ Therapeutics Inc. Formulations de facteur ix lyophilisées
US9351945B1 (en) * 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
GB2536703B (en) * 2015-03-27 2020-12-02 Ge Healthcare Bio Sciences Ab Method for baseline correction in a chromatogram
EP3081942A1 (fr) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Liquide de transmission de pression pour analyseur cellulaire, analyseur cellulaire et procédé d'analyse d'un échantillon cellulaire liquide
EP3782575A1 (fr) 2015-06-04 2021-02-24 Endomagnetics Ltd. Matériaux et formes de marqueur pour localisation à marqueur magnétique
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ,エルエルシー 凍結乾燥方法
JP7541993B2 (ja) 2019-03-14 2024-08-29 テルモ ビーシーティー バイオテクノロジーズ,エルエルシー 凍結乾燥用ローディングトレイ組立体、凍結乾燥システム及び凍結乾燥方法
US12036187B2 (en) * 2019-05-01 2024-07-16 Southwest Research Institute Compositions of dimethyl trisulfide (DMTS) as a cyanide antidote
US20220387416A1 (en) * 2019-10-25 2022-12-08 Cmc Pharmaceuticals, Inc. Atropine-scopolamine with enhanced stability
IL272145A (en) 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic compositions with protein concentrate from conditioned medium of adipose-derived stem cells
US12274450B2 (en) * 2020-08-03 2025-04-15 Transluminal Systems, Llc Devices and methods for trans-arterial osmotic embolization of pathological tissue

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
US4364861A (en) 1980-05-27 1982-12-21 Cutter Laboratories, Inc. Blood-coagulation-promoting products and methods of preparing them
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
PT2193809E (pt) 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
US20010031721A1 (en) * 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
ES2676644T3 (es) * 2003-12-19 2018-07-23 Novo Nordisk Health Care Ag Composiciones estabilizadas de polipéptidos de factor VII
EP1720519A1 (fr) * 2004-03-04 2006-11-15 Wyeth Procede de lyophilisation permettant d'ameliorer la cristallisation de l'excipient
UA97234C2 (ru) 2005-11-01 2012-01-25 Уайєт Раствор хлорида натрия для восстановления влагосодержания композиции лиофилизированного фактора ix

Also Published As

Publication number Publication date
WO2007053533A3 (fr) 2007-12-06
US20200338199A1 (en) 2020-10-29
PL3225233T3 (pl) 2019-12-31
CN101351190B (zh) 2013-01-02
DK1942868T4 (da) 2023-11-06
HUE033949T2 (hu) 2018-01-29
WO2007053533A2 (fr) 2007-05-10
ES2749574T3 (es) 2020-03-23
SI1942868T1 (sl) 2017-07-31
NO20082180A (no) 2008-07-04
ES2627684T5 (es) 2024-04-29
KR101126670B1 (ko) 2012-04-23
PL1942868T3 (pl) 2017-09-29
EP1942868B1 (fr) 2017-04-19
PT3225233T (pt) 2019-10-24
US20070135343A1 (en) 2007-06-14
CA2626531C (fr) 2011-11-29
TW200803915A (en) 2008-01-16
IL190843A (en) 2013-08-29
FI1942868T4 (fi) 2023-10-12
SI3225233T1 (sl) 2019-10-30
BRPI0618133A2 (pt) 2011-08-16
DK1942868T5 (da) 2024-01-08
AR056748A1 (es) 2007-10-24
AU2006308921C1 (en) 2013-01-24
SI1942868T2 (sl) 2023-12-29
EP3593790A1 (fr) 2020-01-15
NO20082180L (no) 2008-07-04
EP3225233B1 (fr) 2019-08-14
WO2007053533A8 (fr) 2008-07-24
HUS2000003I1 (hu) 2020-02-28
HK1245090B (en) 2020-04-09
JP5555425B2 (ja) 2014-07-23
GT200800037A (es) 2008-10-01
AU2006308921A1 (en) 2007-05-10
NO347263B1 (no) 2023-08-14
ECSP088485A (es) 2008-06-30
KR20110128957A (ko) 2011-11-30
FR20C1005I1 (fr) 2020-03-20
PL1942868T5 (pl) 2023-12-27
LUC00035I1 (fr) 2017-09-28
PT1942868T (pt) 2017-06-16
HUE045421T2 (hu) 2019-12-30
KR20080065689A (ko) 2008-07-14
CN101351190A (zh) 2009-01-21
RU2432157C2 (ru) 2011-10-27
AR112443A2 (es) 2019-10-30
PE20110803A1 (es) 2011-11-07
MY184364A (en) 2021-04-01
US20170021022A1 (en) 2017-01-26
EP1942868A2 (fr) 2008-07-16
NZ567685A (en) 2011-07-29
US20200138952A1 (en) 2020-05-07
CR9958A (es) 2008-07-29
IL190843A0 (en) 2008-11-03
EP3225233A1 (fr) 2017-10-04
JP2009513705A (ja) 2009-04-02
HUS1700035I1 (hu) 2017-11-28
EP1942868B2 (fr) 2023-10-04
UA97234C2 (ru) 2012-01-25
RU2008119514A (ru) 2009-12-10
TWI480063B (zh) 2015-04-11
PE20151284A1 (es) 2015-10-05
DK1942868T3 (en) 2017-06-26
ES2627684T3 (es) 2017-07-31
CA2626531A1 (fr) 2007-05-10
DK3225233T3 (da) 2019-10-14
AU2006308921B2 (en) 2012-07-19
PE20070714A1 (es) 2007-07-20

Similar Documents

Publication Publication Date Title
BE2025C533I2 (fr)
BE2024C510I2 (fr)
BE2023C529I2 (fr)
BE2021C552I2 (fr)
BE2021C557I2 (fr)
BE2021C531I2 (fr)
BE2021C524I2 (fr)
BE2021C519I2 (fr)
BE2021C513I2 (fr)
BE2020C531I2 (fr)
BE2020C511I2 (fr)
BE2020C508I2 (fr)
BE2020C004I2 (fr)
BE2019C521I2 (fr)
BE2019C503I2 (fr)
BE2018C037I2 (fr)
BE2018C035I2 (fr)
BE2018C019I2 (fr)
BE2018C016I2 (fr)
BE2017C028I2 (fr)
BE2019C533I2 (fr)
BE2017C007I2 (fr)
BE2018C028I2 (fr)
LUC00035I1 (fr)
BE2015C074I2 (fr)